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ATP-sensitive K+ (KATP) channels composed of potassium inward-rectifier type 6.2 and sul-
fonylurea receptor type 1 subunits (Kir6.2/SUR1)4 are expressed in various cells in the brain
and endocrine pancreas where they couple metabolic status to membrane potential. In β-
cells, increases in cytosolic [ATP/ADP]c inhibit KATP channel activity, leading to membrane
depolarization and exocytosis of insulin granules. Mutations in ABCC8 (SUR1) or KCNJ11
(Kir6.2) can result in gain or loss of channel activity and cause neonatal diabetes (ND) or
congenital hyperinsulinism (CHI), respectively. SUR1 is reported to be a Mg2+-dependent
ATPase. A prevailing model posits that ATP hydrolysis at SUR1 is required to stimulate open-
ings of the pore. However, recent work shows nucleotide binding, without hydrolysis, is
sufficient to switch SUR1 to stimulatory conformations.The actions of nucleotides, ATP and
ADP, on ND (SUR1E1506D) and CHI (SUR1E1506K) mutants, without Kir6.2, were compared to
assess both models. Both substitutions significantly impair hydrolysis in SUR1 homologs.
SUR1E1506D has greater affinity for MgATP than wildtype; SUR1E1506K has reduced affinity.
Without Mg2+, SUR1E1506K has a greater affinity for ATP4− consistent with electrostatic
attraction between ATP4−, unshielded by Mg2+, and the basic lysine. Further analysis of ND
and CHI ABCC8 mutants in the second transmembrane and nucleotide-binding domains
(TMD2 and NBD2) found a relation between their affinities for ATP (±Mg2+) and their clin-
ical phenotype. Increased affinity for ATP is associated with ND; decreased affinity with
CHI. In contrast, MgADP showed a weaker relationship. Diazoxide, known to reduce insulin
release in some CHI cases, potentiates switching of CHI mutants from non-stimulatory to
stimulatory states consistent with diazoxide stabilizing a nucleotide-bound conformation.
The results emphasize the greater importance of nucleotide binding vs. hydrolysis in the
regulation of KATP channels in vivo.
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INTRODUCTION
Neuroendocrine ATP-sensitive K+ channels, (SUR1/Kir6.2)4, cou-
ple cell metabolism with K+ efflux, and thus membrane potential,
in various neurons and endocrine cells including pancreatic isletα-
,β-, and δ-cells whose secretory hormones maintain glucose home-
ostasis. These channels are regulated, in part, by the ATP/ADP
ratio. Both nucleotides bind the Kir6.2 pore to reduce the open
channel probability (Po), while Mg-nucleotide interactions with
SUR1 antagonize this effect. The nucleotide effects are modulated
further by phosphoinositides, long-chain acyl CoAs, and other
factors. In pancreatic β-cells, increased glucose metabolism and
the subsequent rise in [ATP/ADP]C reduces KATP channel activity
leading to downstream insulin release. Gain-of-function muta-
tions in the genes that encode either subunit, ABCC8 (SUR1) or
KCNJ11 (Kir6.2), lead to channel hyperactivity, which attenuates
the insulin response to hyperglycemia and causes neonatal diabetes
mellitus (ND). Conversely, mutations that reduce channel activity
cause congenital hyperinsulinism (CHI) characterized by excess
insulin release even during hypoglycemia. ND and CHI mutations
perturb regulation of channel activity by at least three distinct
mechanisms. Mutations alter either (1) the intrinsic, i.e., ligand-
independent, open channel probability, (2) nucleotide inhibition
at the Kir pore or (3) Mg-nucleotide-dependent stimulation via
SUR1. Additionally, CHI can be due to mutations that disturb traf-
ficking and/or assembly thus reducing the number of functional
channels at the plasma membrane (1–3).
SUR1, like other members of the ATP binding cassette fam-
ily, is reported to have a low level of Mg2+-dependent ATPase
activity (4, 5). A current, generally accepted model for KATP chan-
nel regulation posits that only post-hydrolytic, MgADP-bound
enzymatic intermediates or conformations of SUR1 antagonize
nucleotide inhibition at the pore, i.e., that MgATP hydrolysis
on SUR1 is required to stimulate channel activity [see Ref. (6)
for review]. In line with the current regulatory model, previous
studies have argued that SUR1 ND mutations, specifically those
that increase Mg-nucleotide-dependent stimulation, increase the
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SUR1 catalytic rate and/or reduce the off-rate of the MgADP•Pi
products, thereby augmenting the population of post-hydrolytic
stimulatory intermediates (4, 5). A similar argument has been
made for the S1369A polymorphism in SUR1, which is reported
to increase ATPase activity and thus to increase the risk for type 2
diabetes (7). In contrast to the conventional regulatory model, we
have reported that ATP binding, without hydrolysis, switches SUR1
from conformations with high affinity for the channel antagonist,
glibenclamide (GBC, glyburide in the United States), to confor-
mations with lower affinity for GBC and higher affinity for the
channel agonist, diazoxide, i.e., from non-stimulatory to stimula-
tory states (8, 9). This was demonstrated by removing the Mg2+
cofactor required for hydrolysis and by mutating the highly con-
served catalytic glutamate, E1506, to glutamine (SUR1E1506Q), a
substitution that strongly impairs hydrolysis in SUR1 homologs
[see, for example, Ref. (10–13)]. Structural studies of ABC pro-
teins indicate that ATP drives dimerization of the cytosolic NBDs
upon binding at two sites at the dimer interface. NBD dimer-
ization reconfigures the transmembrane helix bundles (TMD1
and TMD2) from inward-facing to outward-facing orientations
[see Ref. (14) for review]. Thus, we proposed that nucleotide-
bound (MgATP and/or MgADP) outward-facing conformations
of SURs stimulate KATP channel openings. In support of this
updated model, we have also reported that ND mutations distal
from the NBDs, SUR1Q1178R and SUR1R1182Q, increase affinity for
ATP and ADP (9). The current regulatory model predicts that
substitutions that impair hydrolysis should impede conforma-
tional switching thus leading to underactive channels and CHI.
However, a recent report indicates that two catalytic glutamate
substitutions, both predicted to impair hydrolysis, lead to opposite
disease phenotypes; SUR1E1506D produces hyperactive channels
and thus ND while SUR1E1506K forms underactive channels lead-
ing to CHI (15). Here, we test the effect of these substitutions
on nucleotide affinity by assessing changes in nucleotide-induced
conformational switching of SUR1. We found that MgATP affin-
ity correlates with clinical phenotype. The E1506D substitution
increases the affinity of SUR1 for MgATP while E1506K reduces
affinity. In the absence of Mg2+, however, the E1506K substitu-
tion increases affinity for ATP4−, supporting the argument that
the Mg2+ counterion normally shields the catalytic carboxy-
late, but is repelled by the substituted lysine. Both substitutions
reduce affinity for MgADP, consistent with electrophysiological
data indicating that E1506D and E1506K produce channels that
are less sensitive to stimulation by MgADP. To support the revised
regulatory model and investigate the physiologic relevance of
variations in the affinity of SUR1 for nucleotides we tested a
larger pool of ND and CHI substitutions in TMD2 and NBD2
and found that ND mutations showed an increase in the affin-
ity of SUR1 for ATP while CHI mutations showed a reduced
affinity.
MATERIALS AND METHODS
REAGENTS
[3H]glibenclamide, 5-chloro-N -(4-[N -(cyclohexylcarbamoyl)
sulfamoyl]phenethyl)-2-methoxybenzamide, NET1024250UC at
40–70 ci/mmol was purchased from Perkin-Elmer, Inc., Waltham,
MA, USA.
PLASMIDS, CELLS, AND MEMBRANES
The methods used to generate plasmids, to express wildtype (WT)
and mutant SUR1 in Pichia pastoris and to isolate membranes
were described previously (9) and modified to reduce carryover
of endogenous nucleotides, which might affect mutant receptors
with highest affinities for nucleotides (8). Amino acid numbering
is based on Reference Sequence NM_000352.4. It is worth noting
that there are two transcript variants of SUR1/ABCC8 with lengths
of 1581 and 1582 amino acids, respectively. Reference sequences
NM_000352.2, NM_000352.3, and NM_000352.4 all specify the
1581 variant referred to as “variant 2” in the NCBI data base.
“Variant 1,” with 1582 amino acids, is found in NCBI Reference
Sequence: NM_001287174.1. Both variants are expressed in islet
cells, with variant 1 being somewhat more frequent (16). It is
thus likely that KATP channels contain a random assortment of
both variants. Our unpublished electrophysiological data found
no difference between channels of either variant alone (Andrey
Babenko and Joseph Bryan). We have used Reference Sequence
NM_000352.4 in keeping with most recent reports on ABCC8
mutations producing ND and/or CHI.
[3H] GBC BINDING STUDIES
Saturation binding assays
Values for KG, the dissociation constant for [3H]GBC from WT
and mutant SUR1 in the absence of added nucleotide, was assessed
using saturation binding. Membranes containing WT or mutant
SUR1 (~150 pM) were suspended in a Mg2+-free physiological salt
solution (139 mM NaCl, 5 mM KCl, 1 mM EDTA, 50 mM HEPES,
pH 7.4) with increasing concentrations of [3H]-labeled GBC.
Following incubation for 30 min at 37°C, unbound ligand was
removed by rapid filtration as described (17) to determine total
bound ligand. Non-specific binding was determined in the pres-
ence of 1µM unlabeled GBC. Specific GBC binding is defined as:
Total Bound = BMAX × G
KG + G + Non Specific
Where BMAX is the total amount of receptor, G is the concentration
of free [3H]-labeled GBC in the reaction, KG is the equilibrium
dissociation constant of GBC, and Non-Specific is the amount of
non-specific binding typically 10–15% of total bound [3H]GBC.
Nucleotide inhibition assays
Nucleotide-induced conformational changes in SUR1 were
assessed by measuring [3H]GBC binding at varying nucleotide
concentrations. [3H]GBC was held fixed at 1 nM and included the
indicated concentrations of nucleotides with or without added
Mg2+. A creatine phosphokinase-based ATP-regenerating system
was used to maintain constant ATP concentrations over a 30 min
incubation in experiments with MgATP (free [Mg2+]> 1 mM)
(18). The stability of ATP levels was verified by luciferase assays
(Sigma Chemical Co.). MgADP assays included 10 mM AMP to
inhibit endogenous adenylate kinase activity and thus minimize
ATP production. The free Mg2+ level was 1 mM in experiments
with MgADP and MgATP analogs where the ATP-regenerating sys-
tem was not used. Mg2+-free experiments included 1 mM EDTA.
Non-specific binding, typically ~10–15% of total bound, was
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determined in the presence of 1µM unlabeled GBC. The results
are plotted as:
Specific Bound GBC = Specific Bound(+X)
Specific Bound(−X)
where X is the reagent whose effect is being assayed, e.g.,±ATP4−,
±MgATP, etc.
Allosteric analysis
Adenine nucleotides have a negative allosteric action on the bind-
ing of GBC to SUR1 (17, 19, 20). This action is ascribed to
nucleotide-dependent switching between a nucleotide-free con-
formation with highest affinity for [3H]GBC and a nucleotide-
bound state with reduced affinity (9). We hypothesize that these
states are the inward vs. outward-facing conformations of SURs,
respectively. A four-state equilibrium model, Figure 1, has been
used to analyze the effects of nucleotides on GBC binding. SUR1,
like several other ABCC subfamily members, is an asymmetric
ABC protein. NBD1, the degenerate site, has a greater affin-
ity for ATP and is presumed to have little or no enzymatic
activity, while NBD2 has a lower affinity and ATPase activity.
The four-state model presumes NBD1 is nearly saturated at the
nucleotide concentrations needed to switch conformations. This
is a reasonable assumption for WT SUR1 and the CHI mutants,
but may be problematic for ND mutations with higher affinity
for ATP.
FIGURE 1 | Four-state equilibrium model. R, RG, RT, and RTG represent
the unliganded receptor, R, and receptors with GBC (G), ATP (T), or
GBC+ATP bound, respectively. KG and KT are equilibrium dissociation
constants, for GBC and ATP, respectively; β is an allosteric constant; values
of β> 0 reflect a reduced affinity of nucleotide-bound SUR for [3H]GBC. At
given values of KG and KT, β specifies the plateau value at a saturating
concentration of nucleotide. The cartoons represent the conformations of
the four states based on homology models of SUR1 closed and open states
derived from crystal structures of evolutionarily related bacterial ABC
exporters in the presence (31, 32) and absence of nucleotides (33, 34),
respectively.
Derivation of the equations for the four-state equilibrium
model followed Wyman and Gill (21) as described (9). The binding
equation was obtained from the binding partition function,
P = [R] + [RG] + [RT] + [RTG]
R
,
the sum of the contributions of the different species relative to
one reference species, taken here as the unliganded receptor, R.
Substituting the dissociation constants gives a binding polynomial:
P = 1+ [G]
KG
+ [T ]
KT
+ [G][T ]
βKGKT
.
G¯, the amount of [3H]GBC specifically bound per mole of
SUR1, dependent on both [G] and [ATP], is given by:
G¯ = ∂InP
∂InG
= [G]
P
∂P
∂G
This can be expressed as a binding isotherm:
G¯ =
G
(
1
KG
+ TKGKTβ
)
1+ GKG + TKT + GTKGKTβ
where KG and KT are the equilibrium dissociation constants for
GBC and ATP (T), respectively. β is an allosteric constant; val-
ues of β> 0 indicate a reduced affinity of nucleotide-bound SUR
for [3H]GBC. The experimental data, Specific Bound GBC, are
modeled by:
Specific Bound GBC = G¯
G¯T=0
.
Values for KT and β were estimated by fitting the four-state
model to plots of Specific Bound GBC vs. [nucleotide (T)]
with fixed KG values that were determined independently using
saturation binding assays as described above.
STATISTICS
Where indicated the IC50 values were estimated by fitting a logis-
tic equation using Origin 2015 (OriginLab Corp., Northampton,
MA, USA). The means ±SE are plotted; the number of replicate
experiments varies, but n≥ 3 in all cases. ND mutation data are
given in red, CHI mutation data are in blue, and WT data are in
black throughout. The fitting parameters and SE derived using
a four-state model were estimated using Mathematica (Wolfram
Research Inc., Champaign, IL, USA). Figures were prepared using
Origin 2015.
RESULTS
SPECIFIC MUTATIONS HAVE LITTLE TO NO EFFECT ON THE AFFINITY OF
INWARD FACING, NUCLEOTIDE-FREE CONFORMATIONS OF SUR1 FOR
[3H]GBC
To assess the effect of the ABCC8/SUR1 mutations used in this
study on GBC binding the dissociation constants, KG, were deter-
mined in saturation binding assays in the absence of nucleotides
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and Mg2+. SUR1, like other ABC proteins, is presumably in
the inward-facing conformation under this condition. These
mutations are not at the putative sulfonylurea binding site
[reviewed in Ref. (22, 23)] and have only small effects on GBC
binding (see KG values in Table 1).
Two substitutions, E1506D and E1506K, causes of ND and CHI,
respectively, have opposite effects on the affinity for MgATP
Several ND mutations in SUR1 increase the apparent affinity for
ATP (8, 9). To extend these observations two SUR1 substitutions,
E1506D and E1506K, well studied at the electrophysiological level
(15) and identified with ND and CHI, respectively, were ana-
lyzed. E1506 is the essential “catalytic glutamate” in the second
nucleotide-binding domain (NBD2) of SUR1 that positions a
water molecule for attack on the γ-PO4 of ATP (Figure 2A). Sub-
stitution of a glutamine (Q) for glutamate (E) at this position
results in loss of ATPase activity in other members of the ABC
family and has been used to stabilize the nucleotide-bound con-
formation of other ABC proteins for structural studies. MgATP
binding to SUR1E1506Q, shown for reference, switches the con-
formation of SUR1 from a state with high affinity for GBC to
one with a ~40-fold reduced affinity. The estimated affinity of
SUR1E1506Q for MgATP is several hundred folds greater than WT
SUR1 (8). Figure 2B shows that SUR1E1506D also has a greater
affinity for MgATP than WT SUR1, while SUR1E1506K has a consid-
erably weaker affinity. The substitution of lysine for glutamate at
position 1506 replaces a negative with a positive charge. On simple
electrostatic grounds this charge substitution is expected to make
the binding of MgATP less favorable when the β,γ phosphates are
shielded by Mg2+ counterions, which is observed.
Wildtype SUR1 is potentially in a steady-state, slowly hydrolyz-
ing MgATP, while the E1506D and E1506K substitutions are both
expected to impair hydrolysis. The reported hydrolytic rates for
WT SUR1, under similar conditions, are low and, as described
below, the dissociation constant for MgADP is lower than that of
MgATP implying product inhibition. Comparison of the approx-
imate EC50 values, 50 mM, 900µM and 10µM for E1506K, WT
and E1506D, respectively, suggests there is an ~5000-fold range in
affinities. For comparative purposes, the KT values in Table 1 were
estimated from a four-state model assuming the effects of hydroly-
sis are minimal. This gives a comparable, ~2500-fold difference in
affinities for MgATP for SUR1E1506K vs. SUR1E1506D, respectively.
SUR1E1506D and SUR1E1506K both have increased affinity for ATP 4−
While eliminating Mg2+ counterions generally reduces SUR1
affinity for ATP (8, 9), Figure 2C shows that the rank order of
the mutations is changed; SUR1E1506K now has a greater affinity
for ATP4− than SUR1E1506D, the reverse of the result for MgATP.
The results imply that without Mg2+, electrostatic interactions
between lysine and phosphate favor ATP binding to SUR1E1506K.
The data support the argument that the Mg2+ counterion, chelated
by the ATP β, γ-phosphates, shields the catalytic glutamate, and
that the shorter aspartate and neutral glutamine side chains reduce
electrostatic repulsion with the γ-phosphate to improve ATP bind-
ing. The results (Table 1) are consistent with the hypothesis that at
physiologic concentrations of MgATP SUR1E1506D would spend
more time in conformations that stimulate KATP channel activ-
ity vs. WT SUR1, whereas SUR1E1506K would spend less time in
stimulatory conformations.
SUR1E1506D and SUR1E1506K both have reduced affinity for MgADP
The current regulatory model suggests that ND and CHI
mutations would have opposite effects on either the rate of
catalysis or the affinity for MgADP. Since both E1506 sub-
stitutions are predicted to impair hydrolysis, we tested their
effects on MgADP-induced conformational switching. Contrary
Table 1 | Comparison of binding parameters for neonatal diabetes and congenital hyperinsulinism mutations.
Mutation Reference KG KT (+Mg2+) β KT (−Mg2+) β KD (+Mg2+) β
nM µM µM µM
E1506Qa (8) 0.6±0.2 0.9±0.2 40±20 94±9 40±11 211±34 7.6±2.2
E1506Da (15) 0.4±0.04 3.2±1 8.6±1.5 5570±1200 7.2±1.5 289±122 4.7±2.2
Q1178Rb (24) 1.0±0.1 9.2±1.3 10±1 1030±200 9.1±1.7 13.9±2.0 20.7±8.9
I1424V (24) 0.5±0.03 7.1±2.2 5.6±0.7 2840±700 7.6±1.5 12.1±3.7 14.8±6.5
R1182Qb (24) 0.5±0.15 13.1±2.3 10.3±1.4 11100±1600 4.1±0.4 13.1±2.2 16.4±4.6
WT 0.25±0.02 200±18 13±1 10900±3400 16±11 60±16 14±6.6
S1185Ac (9) 0.3±0.05 416±75 4.9±0.5 19100±3600 6.4±1.5 36.6±8 10.4±2.5
C1174Fc (9) 0.5±0.04 2690±725 5.9±2.3 >20000 13±6 66±13 7.6±1.7
E1506K (25) 0.3±0.03 8450±1200 5.5±0.6 256±55 5.3±0.4 >1000 n.d.
G1479R (26) 0.5±0.04 >10000 n.d. >20000 n.d. >1000 n.d.
aIncludes data from Ref. (8).
bIncludes data from Ref. (9).
cPersonal communication, Dr. Lydia Aguilar-Bryan.
ND mutations in red; CHI in blue.
KG, KD, and KT are the dissociation constants for GBC, ADP, and ATP, respectively.
β is an allosteric constant defined in Section “Materials and Methods.”
Patients with E1506K (27) and G1479R (26, 28) mutations are responsive to diazoxide.
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FIGURE 2 | (A) Representation of NBD2 based on Sav1866. Comparison of
MgATP-induced conformational switching by MgATP (B) or ATP4− (C). Here
and in subsequent figures ND mutation data are in red, CHI mutation data
are in blue, and wildtype (WT) data are in black.
to the current regulatory model, both E1506 substitutions have
reduced affinity for MgADP (Figure 4), consistent with elec-
trophysiological data demonstrating that SUR1E1506D/Kir6.2 and
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FIGURE 3 | Comparison of nucleotide-induced conformational
switching inWT and SUR1 mutants. (A) MgATP. (B) ATP4− +0.1 mM
EDTA.
SUR1E1506K/Kir6.2 channels are less sensitive to MgADP stimu-
lation (15). The neutral E1506Q substitution leads to a similar
reduction in MgADP affinity (8).
The affinity of SUR1 for ATP correlates with clinical phenotype
The results for SUR1E1506D vs. SUR1E1506K and prior data on SUR1
ND mutations (8, 9) suggested a possible correlation between the
affinity of a mutant SUR1 for ATP and its clinical phenotype, i.e.,
ND vs. CHI. To support this hypothesis we analyzed additional
mutations including I1424V (ND) and G1479R (CHI) in NBD2
and a cluster of disease causing mutations in TMD2: C1174F
(CHI), S1185A (CHI), Q1178R (ND), and R1182Q (ND). We pre-
viously showed that SUR1Q1178R and SUR1R1182Q, which are on
transmembrane helix 15, have an increased affinity for ATP (9).
Figure 3A shows that there is a strong correlation of ND (shown
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in red) and CHI mutations (shown in blue) with their respec-
tive clinical phenotype. An increased affinity for MgATP vs. WT
SUR1 associates with ND, a decreased affinity with CHI. In other
words, the ND mutants switch to a stimulatory conformation,
with reduced affinity for glibenclamide, at lower concentrations
of nucleotide.
In terms of the conventional model, this correlation could
reflect differences in ATPase activity that result, for example, in
an increase in the stimulatory MgADP-bound form of SUR1.
To assess this possibility directly, we reduced the concentration
of Mg2+ to submicromolar levels to eliminate ATP hydrolysis
and reassessed conformational switching with ATP4−. Figure 3B
shows that, with the exception of SUR1E1506K discussed above,
the ND substitutions all have greater affinities for ATP4− than
WT SUR1; the CHI mutations all have reduced affinity. The data
for SUR1E1506Q are provided for comparison. For quantitative
comparison hydrolysis, in the absence of Mg2+, was assumed to
be negligible and a four-state equilibrium model was fit to the
data. The estimates for KT, the ATP dissociation constant and the
allosteric constant β are given in Table 1; the curves in Figure 3
were calculated using the four-state model.
MgADP affinity is weakly correlated with clinical phenotype
Based on the conventional regulatory model, in which the post-
hydrolytic,MgADP-bound conformation is presumed to be stimu-
latory, one would anticipate the ND mutants might display greater
affinities for MgADP vs. CHI mutants. Figure 4 shows that this
is not the case. While three of four ND mutants have a higher
affinity for MgADP, SUR1E1506D has a significantly weaker affinity
than WT SUR1; two of four CHI mutants have lower affinities for
MgADP vs. WT, but the affinities of SUR1S1185A and SUR1C1174F
are nearly indistinguishable from WT. It is more difficult, however,
to quantify differences in ADP affinity. Membrane preparations
have significant endogenous adenylate kinase activity that gen-
erates ATP. This activity is partially suppressed by the addition
of 10 mM AMP, which alone has no effect on conformational
switching. At the higher MgADP levels required to switch con-
formations of some of the mutant receptors the generated MgATP
becomes a significant factor. At 300µM MgADP, ~4µM MgATP
is generated in our assays (9) and is expected to have significant
effects, for example, on SUR1E1506Q and SUR1E1506D, which have
higher affinities for MgATP, KT values of ~1 and 3µM, respec-
tively. The results for these mutants suggest MgADP may bind,
but not switch conformations and thus may act as a competitive
inhibitor. Thus, we have not attempted to compare the actions of
MgADP quantitatively.
Diazoxide sensitivity of CHI mutants
Some CHI patients respond to diazoxide therapy and we showed
previously that diazoxide, which binds at a site distinct from the
NBDs and the GBC binding site, has a positive allosteric effect
on MgATP binding to SUR1, i.e., diazoxide interacts preferentially
with the nucleotide-bound conformation of SUR1 to stabilize an
outward-facing configuration with reduced affinity for GBC (9).
We assessed whether diazoxide had a similar action on these CHI
mutants by measuring GBC binding at a constant concentration
of MgATP (1 mM). Figure 5 shows that diazoxide potentiates the
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FIGURE 4 | MgADP-induced conformational switching inWT and SUR1
mutants.
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FIGURE 5 | Diazoxide potentiates conformational switching inWT and
CHI SUR1 mutants. For comparison, the results are normalized to GBC
binding in 1 mM MgATP; the data in the inset are normalized to GBC
binding in the absence of ATP and show the effect of added nucleotide on
each mutant.
action of 1 mM MgATP on these CHI mutants. The inset shows the
relative levels of conformational switching of three CHI mutants
by 1 mM MgATP vs. WT SUR1 and indicates the action of diazox-
ide is effectively the same on each mutant. The result implies these
mutations are at residues distinct from the diazoxide binding site
and do not significantly affect either the SUR1/diazoxide interac-
tion or the allosteric linkage between the GBC, ATP, and diazoxide
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binding sites. Patients with the G1479R and E1506K substitutions,
as dominant mutations, were responsive to diazoxide (26–29).
DISCUSSION
Mutations in ABCC8/SUR1, the regulatory subunit of KATP chan-
nels, are known causes of ND and CHI. The main finding of this
study is the direct correlation between the apparent affinities of
mutant SURs for MgATP and their associated clinical phenotype,
i.e., ND vs. CHI. With one informative exception, SUR1E1506K, the
affinities for ATP4− follow the same pattern; a stronger affinity
for ATP correlates with ND, weaker affinities correlate with CHI.
While we cannot “grade” the clinical phenotype, especially since
phenotypes and siblings carrying the same mutation can differ
in disease severity, these results establish a relationship between
the allosteric properties of SUR1 and clinical phenotype. Know-
ing how to manipulate these allosteric properties would have clear
translational relevance for treating these genetic disorders and type
2 diabetes. The exception to the rule is SUR1E1506K, which exhibits
the expected reduced affinity for MgATP, the physiologic ligand,
but a significantly increased affinity for ATP4−. We assume, on
simple electrostatic grounds, that without Mg2+, the positively
charged lysine must attract the phosphates of ATP. The results
support earlier studies showing that ATP binding, not hydrolysis,
is essential for switching SUR1 from a configuration with highest
affinity for sulfonylureas, KATP channel antagonists, to a “stim-
ulatory” conformation with weaker GBC affinity, but a stronger
interaction with diazoxide, a KATP channel agonist.
The results for MgADP are more complex. Models that assume
hydrolysis is required to switch SUR1 to a stimulatory conforma-
tion suggest ND mutants would have a greater affinity for MgADP.
While this is correct for some ND mutations, e.g., SUR1Q1178R,
SUR1E1506D has a significantly weaker affinity. As pointed out
above, determining affinities for MgADP is difficult as ATP, gen-
erated by adenylate kinase, becomes significant at higher ADP
concentrations. It is notable that the E1506D, and particularly
the E1506Q, substitutions with higher affinities for ATP are not
switched appropriately by endogenously generated ATP. A possi-
ble interpretation is that MgADP binds, but does not switch these
mutant SURs and thus acts as a competitive inhibitor of ATP. It
is not clear from the analysis of this limited number of mutants
whether this effect is restricted to substitutions for the catalytic glu-
tamate. It is worth emphasizing that based on the relative affinities
of WT SUR1 for MgATP vs. MgADP (200 vs. 60µM) that MgADP
generated by hydrolysis could function as a “product inhibitor” to
slow turnover.
Early studies (17, 19, 20) on the action of KATP channel ago-
nists, including diazoxide suggested ATP hydrolysis was required
for these compounds to stimulate channel activity. A re-evaluation
of these results using both ND and WT SUR1 showed that dia-
zoxide binds preferentially to the ATP-bound form of SUR1 to
potentiate ATP-driven receptor switching. The ATP, diazoxide,
and GBC binding sites are allosterically linked; added diazoxide
effectively increases the affinity of SUR1 for ATP; the ATP-bound
conformation of SUR1 has a reduced affinity for GBC.
Some patients with dominant CHI mutations in ABCC8/SUR1
are responsive to diazoxide therapy (27, 30). However, usage of dia-
zoxide is limited by low affinity and poor selectivity, resulting in
side effects including fluid retention and hypertrichosis. Although
CHI SUR1 mutants in this study exhibit reduced sensitivity to
switching by stimulatory MgATP, our results indicate that diazox-
ide potentiates the switching action of MgATP on mutant SURs;
specifically, high concentrations of diazoxide (≥100µM) enhance
the switching of millimolar MgATP. The data indicate these CHI
mutations neither significantly impair diazoxide binding nor the
positive allosteric linkage between diazoxide and MgATP suggest-
ing that more potent, SUR1 selective diazoxide analogs such as
NN414 could be more effective at switching SUR1 mutants at lower
pharmacological concentrations, thus benefiting CHI patients.
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